Cipla reported INR6.99B in Debt for its fiscal quarter ending in September of 2026.





Debt Change Date
Arca Biopharma USD 0 0 Mar/2025
aTyr Pharma USD 2.28M 478K Jun/2026
Bio Path USD 261K 261K Mar/2025
Brainstorm Cell Therapeutics USD 1.2M 1.2M Mar/2025
Capricor Therapeutics USD 3.38M 0 Mar/2025
Cara Therapeutics USD 0 0 Mar/2025
Cipla INR 6.99B 857M Sep/2026
Dr.Reddys Laboratories INR 71.95B 5.39B Jun/2026
Immunic USD 0 0 Jun/2024
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 0 0 Jun/2022
Sangamo BioSciences USD 0 0 Jun/2022
Sun Pharmaceuticals INR 46.27B 22.65B Mar/2026
TherapeuticsMD USD 93.6M 2.82M Sep/2022
UPL INR 342.4B 106.64B Sep/2026